Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat [1]

European Neuropsychopharmacology

Volumn 6, Issue 4, 1996, Pages 305-310

  Wadenberg, M L ^a,b,d   Salmi, Peter ^a,b   Jimenez, Patricia ^a   Svensson, Torgny ^c   Ahlenius, Sven ^a,c  

^a Astra Arcus AB ^*  (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

antipsychotics; catalepsy; conditioned avoidance; dopamine receptors; rat; serotonin receptors

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; RACLOPRIDE; RITANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RITANSERIN; SALICYLAMIDES;

EID: 0030294642     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00035-1     Document Type: Article

References (39)

1. Ahlenius, S. (1979) An analysis of behavioral effects produced by drug-induced change of dopaminergic neurotransmission in the brain. Scand. J. Psychol. 20, 59-64.
2. 1A agonist 8-OH-DPAT in the rat. Pharmacol. Toxicol. 64, 3-5.
3. Ahlenius, S. and Hillegaart, V. (1986) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre-and postsynaptic inhibition of dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 24, 1409-1415.
4. Andersson, J.L., Nomikos, G.G., Marcus, M., Hertel, P., Mathe, J.M. and Svensson, T.H. (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 374-385.
5. Bacher, N.M. and Kaup, B.A. (1996) Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am. J. Psychiatry 153, 137.
6. 2 receptor subtypes: a family re-united? Trends Pharmacol. Sci. 16, 105-110.
7. Björk, A., Bergman, I. and Gustavsson, G. (1992) Amperozide in the treatment of schizophrenic patients. A preliminary report. In: Meltzer, H.Y. (Ed.), Novel Antipsychotic Drugs. Raven Press, New York, pp. 47-57.
8. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-203.
9. Cote, L. and Crutcher, M.D. (1991) The basal ganglia. In: Kandel, E.R., Schwartz, J.H., Jessel, T.M. (Eds.), Principles of Neural Sciences. Elsevier, New York, pp. 647-659.
10. Deutch, A.Y., Moghaddam, B., Innis, R.B., Krystal, J.H., Aghajanian, G.K., Bunney, B.S. and Charney, D.S. (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4, 121-156.
11. Egbe, P., Engel, J., Gustafsson, B. and Christensson, E. (1990) Amperozide and conditioned behaviour in rats: potentiation by classic neuroleptics and α-methylparatyrosine. Pharmacol. Toxicol. Suppl. 1, 18-21.
12. Fog, R., Randrup, A. and Pakkenberg, H. (1971) Intrastriatal injection of quarternary butyrophenones and oxypertine: neuroleptic effects in rats. Psychopharmacology 31, 224-230.
13. Gelders, Y.G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry 155, 33-36.
14. Gingrich, J.A. and Caron, M.G. (1994) Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16, 299-321.
15. Hollander, M. and Wolfe, D.A. (1973) Nonparametric Statistical Methods. Wiley and Sons, New York.
16. Janssen, P.A.J., Niemegeers, C., Awouters, F., Schellekens, K.H.L., Megens, A.A.H.P. and Meert, T.F. (1988) Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685-693.
17. Johnels, B. (1982) Locomotor hypokinesia in the reserpine-treated rat: drug effects from the corpus striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 17, 283-289.
18. Johnels, B. (1983) Reserpine-induced rigidity in rats: drug effects on muscle tone from corpus striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 19, 463-470.
19. Kapur, S. and Remington, G. (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153, 466-476.
20. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the brain. Biochem. Pharmacol. 34, 2251-2259.
21. 2 antagonist. Mol. Pharmacol. 27, 600-611.
22. Li, C.C. (1964) Introduction to Experimental Statistics. McGraw-Hill, New York.
23. Meltzer, H.Y. (1995) Atypical antipsychotic drugs. In: Bloom, F.E. and Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1277-1286.
24. i values. J. Pharmacol. Exp. Ther. 251, 238-246.
25. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227-235.
26. Owens, M.J. and Risch, S.C. (1995) Atypical antipsychotics. In: Schatzberg, A.F. and Nemeroff, C.B. (Eds.), Psychopharmacology. Press Inc., Washington DC, pp. 263-280.
27. 2 receptor blocker. Drug Dev. Res. 8, 205-211.
28. Salmi, P., Samuelsson, J. and Ahlenius, S. (1994) A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J. Pharmacol. Toxicol. Methods 32, 155-159.
29. 2A receptors in antipsychotic activity. Life Sci, 56, 2209-2222.
30. 4. Neuropsychopharmacology 7, 261-284.
31. Seeman, P. (1995) Dopamine receptors. Clinical correlates. In: Bloom, F.E. and Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 295-302.
32. Siegel, S. and Castellan Jr, N.J. (1988) Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill, New York.
33. 3) as a target for neuroleptics. Nature 347, 146-151.
34. 2 antagonism. In: Vanhoutte, P.M., Saxena, P.R., Paoletti, R., Brunello, N. and Jackson, A.S. (Eds.), Serotonin: From Cell Biology to Pharmacology and Therapeutics. Kluwer Academic Publishers, Dordrecht, pp. 263-276.
35. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266, 684-691.
36. Tamminga, C.A, and Gerlach J. (1987) New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 1129-1140.
37. Wadenberg, M.-L. (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23 390 in the rat. J. Neural Transm. 89, 49-59.
38. Wadenberg, M.-L. and Ahlenius, S. (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83, 43-53.
39. Wadenberg, M.-L., Ericson, E.L., Magnusson, O. and Ahlenius, S. (1990) Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum in the rat. Biol. Psychiatry 28, 297-307.